Navigation Links
Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
Date:1/24/2012

PARSIPPANY, N.J., Jan. 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced preliminary 2011 non-GAAP earnings per share of $4.75-$4.77, a 39 percent increase over 2010 full year earnings during its third annual Investor Meeting in New York City.  Excluding the November 2011 launch of generic Lipitor® which is expected to represent a $0.64 earnings contribution, earnings grew at approximately 20 percent for the full year.  The Company also reported preliminary full year 2011 revenues of approximately $4.57 billion, an increase of 28 percent over 2010.

"The strength of our integrated pharmaceutical business drove exceptional results last year, based on significant performance in our Global Generics business, and sound results for our Global Brands and Anda Distribution operations," said Paul Bisaro, President and CEO of Watson.  "Total revenue grew at approximately 28%, supporting the exceptional 39% growth in earnings. We ended the year with a strong balance sheet that is enabling us to support both the organic growth of our business, while being in the good position to execute on strategic business development activities and investments into all three of our businesses."

The Company noted that its Global Generics revenues of approximately $3.36 billion were driven by the launch of generic Concerta®, by higher generic Lipitor® sales resulting from its ability to maximize the launch opportunity, as well the continued strong performance of its modified-release and oral contraceptive franchises.  In addition, Watson's international generics business performed well, supported by the May 2011 strategic acquisition of Specifar.  The Company said that Global Brands revenues of approximately $440 million, and Anda Distribution revenues of approximately $776 million were in line with its full year forecasts.'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Watson Acquires Ascent Pharmahealth for AU$375 Million
2. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
4. Watson Launches Generic LoSEASONIQUE(R)
5. Watson Launches Generic LIPITOR®
6. Watson to Present at the 2011 Piper Jaffray Health Care Conference
7. Watson Wins Kentucky Drug Pricing Litigation
8. Watson Confirms Exelon(R) Patent Challenge
9. Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA
10. Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
11. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  AnaptysBio, ... of therapeutic antibodies, today announced the appointment of ... Officer. Dr. Londei will lead the preclinical and ... "We are pleased to welcome Dr. ... Hamza Suria , President and Chief Executive Officer ...
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis Alliance ... (HNF), both philanthropies, announced today the creation of ... the treatment of the rare disease known as ... announced its alliance model earlier this month. Today,s ... of a collaborative model where researchers and all ...
Breaking Medicine Technology:AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... , THE WOODLANDS, Texas , Jan. ... that it is changing its name to the Life Beyond Cancer ... the organization aspires to provide to cancer patients and their families. ... local communities by removing barriers to prevention, education, early detection, treatment ...
... , JERUSALEM , ... biopharma company, announced today that it has granted Novartis an option ... Transient Permeability Enhancer (TPE) technology for use with certain related small ... In a separate but related agreement, the MPM Bio IV NVS ...
Cached Medicine Technology:US Oncology Foundation Becomes Life Beyond Cancer Foundation 2US Oncology Foundation Becomes Life Beyond Cancer Foundation 3Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 2Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products 3
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... (HealthDay News) -- New stem cell-based research could improve ... treatments, a new study suggests. Scientists used stem ... in a lab dish. They then transplanted the organoids ... disorders, according to the researchers. "This provides a ... that can cause intestinal failure, from genetic disorders appearing ...
Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... the Bench,-, EL SEGUNDO, Calif., Oct. 16 ... solutions for microarray-based,research, announced today the release of ... that provides easy, fast and powerful platform,independent and ... data sets, simultaneously. NEXUS CGH easily supports ...
... The department of bioengineering at Clemson University has received ... Both the National Institutes of Health (NIH) and a ... (NSBRI www.nsbri.org ), are primary contributors of funds ... application. , The study addresses bone loss that occurs ...
... YORK, Oct. 16 Even though Americans pick up ... toothbrushes,may need a cleaning of their own. Celebrity Dentist ... says a new survey conducted by the,Philips Sonicare brand ... Listen to this report from Philips (NYSE: ...
... Unique Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... Home is,inviting everyone with the name of "Walker" in the United States to ... Walk of,Ages" on December 2 in Reseda. According to official census records there,are ...
... - BCL.P, VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ ... announce that it has entered into an ... (the "Arrangement,Agreement") with iCo Therapeutics Inc. ("iCo"). ... constitute Beanstalk,s,"Qualifying Transaction" as a capital pool ...
... children appear to have a lower risk of asthma ... a non-agricultural rural environment, according to a University of ... 13,524 asthmafree children aged less than 12 years in ... Youth (NLSCY) showed that children living in a farming ...
Cached Medicine News:Health News:BioDiscovery Releases NEXUS CGH Version 2 for DNA Copy Number Analysis and Visualization 2Health News:Clemson awarded $2M to study radiation-induced bone loss 2Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10Health News:Farm kids have lower risk of asthma, study shows 2
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Medicine Products: